Literature DB >> 25445023

Increasing incidence of chronic graft-versus-host disease in allogeneic transplantation: a report from the Center for International Blood and Marrow Transplant Research.

Sally Arai1, Mukta Arora2, Tao Wang3, Stephen R Spellman4, Wensheng He5, Daniel R Couriel6, Alvaro Urbano-Ispizua7, Corey S Cutler8, Andrea A Bacigalupo9, Minoo Battiwalla10, Mary E Flowers11, Mark B Juckett12, Stephanie J Lee13, Alison W Loren14, Thomas R Klumpp15, Susan E Prockup16, Olle T H Ringdén17, Bipin N Savani18, Gérard Socié19, Kirk R Schultz20, Thomas Spitzer21, Takanori Teshima22, Christopher N Bredeson23, David A Jacobsohn24, Robert J Hayashi25, William R Drobyski26, Haydar A Frangoul27, Görgün Akpek28, Vincent T Ho8, Victor A Lewis29, Robert Peter Gale30, John Koreth8, Nelson J Chao31, Mahmoud D Aljurf32, Brenda W Cooper33, Mary J Laughlin34, Jack W Hsu35, Peiman Hematti12, Leo F Verdonck36, Melhelm M Solh37, Maxim Norkin35, Vijay Reddy38, Rodrigo Martino39, Shahinaz Gadalla40, Jenna D Goldberg41, Philip L McCarthy42, José A Pérez-Simón43, Nandita Khera44, Ian D Lewis45, Yoshiko Atsuta46, Richard F Olsson47, Wael Saber5, Edmund K Waller48, Didier Blaise49, Joseph A Pidala50, Paul J Martin13, Prakash Satwani51, Martin Bornhäuser52, Yoshihiro Inamoto13, Daniel J Weisdorf2, Mary M Horowitz5, Steven Z Pavletic53.   

Abstract

Although transplant practices have changed over the last decades, no information is available on trends in incidence and outcome of chronic graft-versus-host disease (cGVHD) over time. This study used the central database of the Center for International Blood and Marrow Transplant Research (CIBMTR) to describe time trends for cGVHD incidence, nonrelapse mortality, and risk factors for cGVHD. The 12-year period was divided into 3 intervals, 1995 to 1999, 2000 to 2003, and 2004 to 2007, and included 26,563 patients with acute leukemia, chronic myeloid leukemia, and myelodysplastic syndrome. Multivariate analysis showed an increased incidence of cGVHD in more recent years (odds ratio = 1.19, P < .0001), and this trend was still seen when adjusting for donor type, graft type, or conditioning intensity. In patients with cGVHD, nonrelapse mortality has decreased over time, but at 5 years there were no significant differences among different time periods. Risk factors for cGVHD were in line with previous studies. This is the first comprehensive characterization of the trends in cGVHD incidence and underscores the mounting need for addressing this major late complication of transplantation in future research.
Copyright © 2015 American Society for Blood and Marrow Transplantation. All rights reserved.

Entities:  

Keywords:  Allogeneic transplant; Incidence; Nonrelapse mortality; cGVHD

Mesh:

Substances:

Year:  2014        PMID: 25445023      PMCID: PMC4326247          DOI: 10.1016/j.bbmt.2014.10.021

Source DB:  PubMed          Journal:  Biol Blood Marrow Transplant        ISSN: 1083-8791            Impact factor:   5.742


  31 in total

1.  Transplantation of peripheral blood stem cells as compared with bone marrow from HLA-identical siblings in adult patients with acute myeloid leukemia and acute lymphoblastic leukemia.

Authors:  O Ringdén; M Labopin; A Bacigalupo; W Arcese; U W Schaefer; R Willemze; H Koc; D Bunjes; E Gluckman; V Rocha; A Schattenberg; F Frassoni
Journal:  J Clin Oncol       Date:  2002-12-15       Impact factor: 44.544

2.  Donor characteristics as risk factors in recipients after transplantation of bone marrow from unrelated donors: the effect of donor age.

Authors:  C Kollman; C W Howe; C Anasetti; J H Antin; S M Davies; A H Filipovich; J Hegland; N Kamani; N A Kernan; R King; V Ratanatharathorn; D Weisdorf; D L Confer
Journal:  Blood       Date:  2001-10-01       Impact factor: 22.113

3.  Acute and chronic graft-versus-host disease after allogeneic peripheral-blood stem-cell and bone marrow transplantation: a meta-analysis.

Authors:  C Cutler; S Giri; S Jeyapalan; D Paniagua; A Viswanathan; J H Antin
Journal:  J Clin Oncol       Date:  2001-08-15       Impact factor: 44.544

4.  Risk factors for chronic graft-versus-host disease after bone marrow transplantation: a retrospective single centre analysis.

Authors:  S Carlens; O Ringdén; M Remberger; B Lönnqvist; H Hägglund; S Klaesson; J Mattsson; B M Svahn; J Winiarski; P Ljungman; J Aschan
Journal:  Bone Marrow Transplant       Date:  1998-10       Impact factor: 5.483

Review 5.  Bone marrow transplantation for myelodysplastic syndrome--who? when? and which?

Authors:  S Luger; N Sacks
Journal:  Bone Marrow Transplant       Date:  2002-08       Impact factor: 5.483

Review 6.  Chronic graft-versus-host disease.

Authors:  Stephanie J Lee; Georgia Vogelsang; Mary E D Flowers
Journal:  Biol Blood Marrow Transplant       Date:  2003-04       Impact factor: 5.742

7.  Severity of chronic graft-versus-host disease: association with treatment-related mortality and relapse.

Authors:  Stephanie J Lee; John P Klein; A John Barrett; Olle Ringden; Joseph H Antin; Jean-Yves Cahn; Matthew H Carabasi; Robert Peter Gale; Sergio Giralt; Gregory A Hale; Osman Ilhan; Philip L McCarthy; Gerard Socie; Leo F Verdonck; Daniel J Weisdorf; Mary M Horowitz
Journal:  Blood       Date:  2002-07-15       Impact factor: 22.113

8.  Acute and chronic graft-versus-host disease after ablative and nonmyeloablative conditioning for allogeneic hematopoietic transplantation.

Authors:  Daniel R Couriel; Rima M Saliba; Sergio Giralt; Issa Khouri; Borje Andersson; Marcos de Lima; Chitra Hosing; Paolo Anderlini; Michelle Donato; Karen Cleary; James Gajewski; Joyce Neumann; Cindy Ippoliti; Gabriela Rondon; Agueda Cohen; Richard Champlin
Journal:  Biol Blood Marrow Transplant       Date:  2004-03       Impact factor: 5.742

9.  An analysis of factors predisposing to chronic graft-versus-host disease.

Authors:  O Ringdén; T Paulin; B Lönnqvist; B Nilsson
Journal:  Exp Hematol       Date:  1985-11       Impact factor: 3.084

10.  Chronic graft-versus-host syndrome in man. A long-term clinicopathologic study of 20 Seattle patients.

Authors:  H M Shulman; K M Sullivan; P L Weiden; G B McDonald; G E Striker; G E Sale; R Hackman; M S Tsoi; R Storb; E D Thomas
Journal:  Am J Med       Date:  1980-08       Impact factor: 4.965

View more
  98 in total

1.  Donor and recipient sex in allogeneic stem cell transplantation: what really matters.

Authors:  Haesook T Kim; Mei-Jie Zhang; Ann E Woolfrey; Andrew St Martin; Junfang Chen; Wael Saber; Miguel-Angel Perales; Philippe Armand; Mary Eapen
Journal:  Haematologica       Date:  2016-06-27       Impact factor: 9.941

Review 2.  Aberrant B-cell homeostasis in chronic GVHD.

Authors:  Stefanie Sarantopoulos; Jerome Ritz
Journal:  Blood       Date:  2015-02-02       Impact factor: 22.113

3.  Targeting PI3Kδ function for amelioration of murine chronic graft-versus-host disease.

Authors:  Katelyn Paz; Ryan Flynn; Jing Du; Stacey Tannheimer; Amy J Johnson; Shuai Dong; Anne-Katrien Stark; Klaus Okkenhaug; Angela Panoskaltsis-Mortari; Peter T Sage; Arlene H Sharpe; Leo Luznik; Jerome Ritz; Robert J Soiffer; Corey S Cutler; John Koreth; Joseph H Antin; David B Miklos; Kelli P MacDonald; Geoffrey R Hill; Ivan Maillard; Jonathan S Serody; William J Murphy; David H Munn; Colby Feser; Michael Zaiken; Bart Vanhaesebroeck; Laurence A Turka; John C Byrd; Bruce R Blazar
Journal:  Am J Transplant       Date:  2019-03-19       Impact factor: 8.086

4.  Analysis of non-relapse mortality and causes of death over 15 years following allogeneic hematopoietic stem cell transplantation.

Authors:  Y Tanaka; S Kurosawa; K Tajima; T Tanaka; R Ito; Y Inoue; K Okinaka; Y Inamoto; S Fuji; S-W Kim; R Tanosaki; T Yamashita; T Fukuda
Journal:  Bone Marrow Transplant       Date:  2016-01-11       Impact factor: 5.483

Review 5.  How I treat refractory chronic graft-versus-host disease.

Authors:  Stefanie Sarantopoulos; Adela R Cardones; Keith M Sullivan
Journal:  Blood       Date:  2019-01-23       Impact factor: 22.113

6.  Host interleukin 6 production regulates inflammation but not tryptophan metabolism in the brain during murine GVHD.

Authors:  Ludovic Belle; Vivian Zhou; Kara L Stuhr; Margaret Beatka; Emily M Siebers; Jennifer M Knight; Michael W Lawlor; Casey Weaver; Misato Hashizume; Cecilia J Hillard; William R Drobyski
Journal:  JCI Insight       Date:  2017-07-20

7.  Steroid Refractory Chronic Graft-Versus-Host Disease: Cost-Effectiveness Analysis.

Authors:  Fevzi F Yalniz; Mohammad H Murad; Stephanie J Lee; Steven Z Pavletic; Nandita Khera; Nilay D Shah; Shahrukh K Hashmi
Journal:  Biol Blood Marrow Transplant       Date:  2018-03-14       Impact factor: 5.742

8.  Upregulation of IFN-Inducible and Damage-Response Pathways in Chronic Graft-versus-Host Disease.

Authors:  Frances T Hakim; Sarfraz Memon; Ping Jin; Matin M Imanguli; Huan Wang; Najibah Rehman; Xiao-Yi Yan; Jeremy Rose; Jacqueline W Mays; Susan Dhamala; Veena Kapoor; William Telford; John Dickinson; Sean Davis; David Halverson; Haley B Naik; Kristin Baird; Daniel Fowler; David Stroncek; Edward W Cowen; Steven Z Pavletic; Ronald E Gress
Journal:  J Immunol       Date:  2016-09-30       Impact factor: 5.422

9.  Collection of hematopoietic CD34 stem cells in rhesus macaques using Spectra Optia.

Authors:  Lynn D Haynes; Jennifer Coonen; Jennifer Post; Kevin Brunner; Debra Bloom; Peiman Hematti; Dixon B Kaufman
Journal:  J Clin Apher       Date:  2016-08-31       Impact factor: 2.821

10.  Phase-1/-2 study of pomalidomide in chronic GvHD.

Authors:  I Pusic; M P Rettig; J F DiPersio; S Bauer; K McFarland; R P Gale; S Z Pavletic
Journal:  Bone Marrow Transplant       Date:  2015-12-14       Impact factor: 5.483

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.